New Research Results Spotlight Rare Molecular Subtypes

Although molecularly targeted therapies have transformed the treatment paradigm for NSCLC, the kaleidoscope of genomic alterations that affects subsets of patients is straining the limits of current diagnostic and clinical discovery approaches.

Related Keywords

United States , Miller School , Florida , University Of Miami , New York , Alexander Drilon , Miller School Of Medicine , Cancer Center , National Comprehensive Cancer Network , Sylvester Comprehensive Cancer Center , Early Drug Development Service , National Cancer Institute , Nature Reviews Clinical , Memorial Sloan Kettering , Mutational Landscape , Small Cell Lung Cancer , Biomarker Testing , International Association , Lung Cancer , Testing Strategies , Rev Clin , Cancer Institute , Molecular Testing , Targeted Therapy , Practice Guidelines , Molecularly Targeted Therapies , Treatment Paradigm For Nsclc , Genomic Alterations , Current Diagnostic And Clinical Discovery Approaches , Subsets Of Patients ,